Grifols

We are proud to share that Grifols has been included in LinkedIn’s inaugural Top Companies list in Barcelona, recognizing the best workplaces to grow professionally. This distinction highlights our ongoing commitment to fostering talent, continuous learning and meaningful career development opportunities for our people. A big thank you to all our teams who make Grifols a place where everyone can thrive and make a real impact. #Grifols #TopCompanies #Talent #CareerGrowth #Barcelona

On Saturday, May 16, we had the honor of welcoming the President of the Government of Catalonia, Salvador Illa, to Grifols’ production plant in Los Angeles, California. This site is one of our key biopharmaceutical manufacturing facilities and is also home to logistics operations and corporate functions. California is one of Grifols’ main operational, industrial and innovation hubs in the United States. Beyond our Los Angeles headquarters, we operate facilities in San Diego, Emeryville, San Carlos and Vista, employing a total of 2,300 people across the state. Grifols is the largest operator in the U.S. plasma market, with nearly 300 donation centers in 40 states and major industrial facilities in California and North Carolina. Altogether, Grifols employs more than 14,000 people nationwide. Over the years, we have built in the United States a vertically integrated, self-sufficient model that spans the entire value chain: from plasma collection and manufacturing to analytical control to logistics, distribution and commercialization. We thank President Salvador Illa for his visit and his interest in Grifols’ work, mission and values. #Grifols #WeAreHealthcare #California

May is GBS & CIDP Awareness Month - an important time to highlight two rare neurological conditions that can significantly impact mobility, independence and quality of life. Guillain-Barré Syndrome (GBS) can progress rapidly, while Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) develops more slowly and can worsen without early intervention. Both conditions can lead to weakness, pain and even paralysis - making timely diagnosis and access to treatment essential. We’re proud to work with patients, healthcare professionals and organizations to help improve diagnosis and access to treatment. Awareness is where progress begins. Together, we can help ensure more people receive the care they need, when they need it. #GBSCIDPAwarenessMonth #GBS #CIDP

We continue to make steady progress in 2026. Today we shared our Q1 results, marking a solid start to the year and performance in line with expectations and reinforcing our objectives for 2026. Results were driven by the continued strength of our Biopharma business, particularly our immunoglobulin portfolio, alongside disciplined execution on efficiency and financial management. We also strengthened our financial position this quarter, including the successful refinancing of our 2027 maturities and making further progress in deleveraging. Our strategic initiatives continued to advance, including the Egypt and Canada self-sufficiency projects We are fully focused on executing our priorities and key initiatives to drive performance in 2026. More details 👉 http://spkl.io/6040A7k70

Grifols has once again been recognized in the Dow Jones Best‑in‑Class World and Europe indices as one of the world’s most sustainable biotechnology companies, for the fifth and sixth consecutive years, respectively. This recognition by S&P Global, through its Corporate Sustainability Assessment (CSA), reflects the depth of sustainability integration across our business and the strength of our ESG performance. This year, we made particularly strong progress in Governance, alongside top‑tier results in Transparency and Reporting, Business Ethics, Information Security and Climate Strategy. Building on this milestone, we will continue advancing our sustainability strategy, strengthening our impact for patients, donors, employees and communities worldwide. More info 👉 http://spkl.io/6041AAvwZ #DJBIC #Sustainability #ESG

As #WorldPIWeek comes to a close, we want to share the story of Holly Bain – a primary immunodeficiency patient (PI) who also happens to be a Grifols employee. 💙 For years, Holly pushed through illness and hospitalizations without a reason why. She says being diagnosed with PI at 33 years old was overwhelming but also freeing. This week, we honor Holly’s story as well as every patient searching for answers – and a sense of freedom. At Grifols, we strive to increase disease awareness, promote early diagnosis, provide education and support and advocate for improved availability of treatment and care. Thank you for joining us in raising awareness for PI and for supporting this year’s global campaign World PI Week 🌎 #WorldPIWeek #PrimaryImmunodeficiency

The 2026 International Plasma Protein Congress, hosted by PPTA in Milan, brought together the global plasma community to exchange insights on the future of plasma‑derived therapies. David Bell, Chief Corporate Development Officer at Grifols, was elected Chairman of the PPTA Global Executive Board of Directors, reflecting strong leadership and long‑standing commitment to the global plasma community. Ahmed Serag, Montse Costa and Clàudia Garcia also took part throughout the congress, sharing perspectives and contributing to discussions across key sessions and panels. Congratulations to Prof. Noel Gerry McElvaney on receiving the Hilfenhaus Award, a well-deserved recognition of his contributions to the alpha-1 field. These conversations reinforce the importance of continued collaboration to advance access, safety and sustainability in PDMPs. Plasma Protein Therapeutics Association (PPTA) PPTA Europe #IPPC2026 #ResilienceReachResponsibility

New Real World Evidence from the AMBAR program was presented at the ASFA 2026 Annual Meeting in Denver through two scientific communications by Dr. Mercè Boada Rovira and Dr. Yahveth Cantero-Fortiz from Ace Alzheimer Center Barcelona AMBAR Center. Results from a real world outpatient cohort show a favorable safety and tolerability profile across more than 1,200 procedures, successful use of peripheral access, and data suggesting a slower cognitive decline, particularly in earlier stages of Alzheimer’s disease. These findings highlight the value of real world evidence to complement clinical trials and support the consistent delivery of AMBAR in routine clinical practice. #ASFA2026 #Apheresis #AMBAR

El impacto de una inmunodeficiencia primaria (IDP) va más allá de lo clínico y alcanza de lleno el bienestar emocional de pacientes y familias. Con el programa “Ya soy mayor. Tengo una IDP y no estoy solo”, impulsado por el Vall d'Hebron Barcelona Hospital Campus junto a la BCN PID Foundation y con la colaboración de Grifols, se ofrece acompañamiento psicológico a quienes conviven con estas patologías. En cinco años, más de 360 personas han participado, muchas de ellas familiares, reflejando el peso emocional que conlleva la enfermedad. Una iniciativa que refuerza la importancia de abordar la salud de forma integral, poniendo también el foco en el apoyo emocional. Más info 👉 http://spkl.io/6045AfvZd #WorldPIWeek

Thanks to Reuters Events Pharma for driving such an important conversation. At Grifols, we’re proud to be part of this dialogue on how stronger collaboration across pharma, tech, and global partners can help expand access to medicines and advance health equity worldwide. We remain committed to developing sustainable, innovative approaches that respond to real healthcare needs and make a lasting impact. 🤝🌍 #REpharma